About Collidion
Collidion is a company based in Petaluma (United States) founded in 2015. Collidion has raised $14.53 million across 3 funding rounds. Collidion has completed 1 acquisition, including Plex Pharmaceuticals. Collidion offers products and services including Anti-infective Technologies, Pharmaceutical Innovations, and Consumer Health Products. Collidion operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Petaluma, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Collidion Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.53 M (USD)
in 3 rounds
-
Latest Funding Round
$14.26 M (USD), Series A
Oct 30, 2019
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Collidion
Collidion offers a comprehensive portfolio of products and services, including Anti-infective Technologies, Pharmaceutical Innovations, and Consumer Health Products.
Develops technologies for anti-infectives and disinfection to improve patient care.
Focuses on treatments for diseases like Parkinson's and cataracts.
Creates products for sterilization and consumer health applications.
People of Collidion
Unlock access to complete
Unlock access to complete
Funding Insights of Collidion
Collidion has successfully raised a total of $14.53M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14.26 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Collidion
Collidion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Plex Pharmaceuticals.
Investment portfolio details for Collidion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Discovering small molecules for diseases caused by protein misfolding such as Parkinson's.
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Collidion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Collidion
Detailed financials for Collidion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Collidion Comparisons
Peer comparison for Collidion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Collidion
Collidion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Collidion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Collidion
Complete news archive for Collidion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Collidion
Collidion was founded in 2015 and raised its 1st funding round 4 years after it was founded.
Collidion is headquartered in Petaluma, United States. It is registered at Petaluma, California, United States.
Collidion is a funded company, having raised a total of $14.53M across 3 funding rounds to date.
Collidion Inc. was founded in 2015 and is headquartered in Petaluma, United States. Operations center on the healthcare sector, where early-stage ideas and research are identified and licensed for advancement into commercial products. Emphasis is given to combating antibiotic resistance, developing drugs against biofilms, and creating delivery systems for both systemic and topical applications.
Collidion's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Collidion offers Anti-infective Technologies, Pharmaceutical Innovations, and Consumer Health Products.
Collidion has made 1 acquisition, including Plex Pharmaceuticals.